| Entries |
| Document | Title | Date |
|---|
| 20080260863 | COMPOSITIONS FOR MUCOCILIARY CLEARANCE AND METHODS FOR ADMINISTERING SAME - Sterile, preservative-free premeasured hypertonic saline solutions may be administered to individuals afflicted with cystic fibrosis to increase mucolciliary clearance and to improve lung function. In particular, a 7% hypertonic saline solution may be administered at least 2 times a day, using a jet and/or vibrating-mesh nebulizer to an individual afflicted with cystic fibrosis. | 10-23-2008 |
| 20090123570 | COMPOSITION AND METHOD FOR TREATING SORE THROAT - The present invention provides compositions and methods for treating sore throat by reducing inflammation and clearing oral-pharyngeal mucus associated with sore throat comprising hypertonic saline and menthol. | 05-14-2009 |
| 20090130230 | SILICATE CONTAINING COMPOSITIONS AND METHODS OF TREATMENT - The present invention relates to compositions comprising a silicate and methods of use thereof. In particular, the compositions of the present invention are suitable for treating inflammatory conditions, cancer, bacterial and viral infections, and infected and uninfected wounds. The compositions of the present invention can also be useful in treating spinal cord injury, tissue remodeling, and promoting bone growth and repair. | 05-21-2009 |
| 20090191282 | CONTROLLED RELEASE COMPOSITION CONTAINING A STRONTIUM SALT - A controlled release pharmaceutical composition comprising a strontium salt. The invention also relates to the use of a strontium salt for treating a male suffering from diseases and conditions affecting metabolism and/or structural integrity of cartilage and/or bone. The invention also relates to the use of a strontium-containing compound for preventing a cartilage and/or bone condition in a subject, and for the treatment and/or prophylaxis of secondary osteoporosis. | 07-30-2009 |
| 20090220620 | Functional Fluid and a Process for the Preparation of the Functional Fluid - A functional fluid for the removal of contaminates such as but not limited to, acid causing components in gas, sulfur components and carbon oxides from fluid streams, and removal and treatment of NO | 09-03-2009 |
| 20090232908 | STABLE AQUEOUS SOLUTION CONTAINING SODIUM PYRUVATE, AND THE PREPARATION AND USE THEREOF - A stable aqueous solution of sodium pyruvate for medical use, which contains mM sodium pyruvate and a stabilizer of sodium pyruvate, wherein the said stabilizer is H | 09-17-2009 |
| 20100143500 | Methods and Compositions for Inhibiting GSK-3 In Glial Cell Related Disorders - A method of treating a glial cell related disorder in a mammalian subject includes administering a drug which enhances or prolongs GSK-3 α or β inactivation. | 06-10-2010 |
| 20100159032 | COMBINATIONS USEFUL FOR THE TREATMENT OF NEURONAL DISORDERS - The present invention provides a method for the treatment of neuronal disorders, in a mammal such as a human, which method comprises administering an effective, non-toxic and pharmaceutically acceptable amount of at least one QC-inhibitor, optionally in combination with at least one agent, selected from the group consisting of PEP-inhibitors, LiCl, inhibitors of DP IV/DP IV-like enzymes, NPY-receptor ligands, NPY agonists, NPY antagonists, ACE-inhibitors, PIMT enhancers, inhibitors of beta secretases, inhibitors of gamma secretases and inhibitors of neutral endopeptidase, to a mammal in need thereof. | 06-24-2010 |
| 20110038953 | STRONTIUM COMPOUND FOR TREATMENT OF SUB-DERMAL SOFT TISSUE PAIN - The invention provides a method of treatment of a human or non-human subject to combat sub-dermal soft tissue pain therein, said method comprising administering to a subject in need thereof an effective amount of a physiologically tolerable strontium compound. | 02-17-2011 |
| 20110189307 | METHODS AND COMPOSITIONS FOR OXYGENATION OF SKIN TO TREAT SKIN DISORDERS - Methods and compositions for treating wounds, decubitus ulcers, diaper rash, burns, abrasions, and other irritations and relevant injuries are provided. The invention contemplates in one embodiment the use of an aqueous or emollient medium having one or more pH raising ingredients in a composition specifically designed to deliver oxygen to the skin's surface. | 08-04-2011 |
| 20110189308 | METHODS TO TREAT NEURODEGENERATIVE CONDITIONS OR DISEASES BY TARGETING COMPONENTS OF A PTEN SIGNALING PATHWAY - The disclosure provides that components of a PTEN cell signaling pathway may be utilized as therapeutic targets for treating, preventing, slowing the progression of or delaying the onset of a neurodegenerative disease or disorder. Such components that may be targeted include, phosphatase and tensin homologue (PTEN), glycogen synthase kinase 3 beta (GSK3β), and AKT. The subject matter disclosed herein relates to the therapeutic use of inhibitors of PTEN, inhibitors of GSK3β, or activators of AKT to treat a neurodegenerative disease or disorder in a subject. Compounds are disclosed which may be used in the methods provided. | 08-04-2011 |
| 20110200686 | COMPOSITIONS OF MODULATORS OF THE WNT/B-CATENIN PATHWAY AND AN N-CINNAMYL-N'BENZHYDRYL PIPERAZINE AND THEIR USE IN TREATING NEOPLASTIC CONDITIONS INCLUDING MALIGNANT MELANOMA - The present invention is directed to a composition comprising a modulator of the Wnt/β-catenin pathway or a pharmaceutically acceptable salt thereof and an N-cinnamyl-N′-benzhydryl piperazine or a pharmaceutically acceptable salt thereof. The present invention is also directed to a method of treating a neoplastic condition in a subject by administering the modulator of the Wnt/βcatenin pathway or a pharmaceutically acceptable salt thereof and an N-cinnamyl-N′-benzhydryl piperazine or a pharmaceutically acceptable salt thereof to the subject under conditions effective to treat a neoplastic disorder. | 08-18-2011 |
| 20110293746 | Modulation of Gsk-3Beta and Method of Treating Proliferative Disorders - There is provided methods and uses for promoting cell death, when combined with chemotherapeutic agents, in an abnormally proliferating cell, and for treating a proliferative disorder in a subject, which methods and uses involve contacting a cell with, or administering to a subject, an agent that modulates glycogen synthase kinase-3β activity to a cell that is being treated with a chemotherapeutic agent. | 12-01-2011 |
| 20120114767 | System and Method for Diagnosis and Treatment of Neuropsychiatric Disorders - An assay for a GCH1 allele and associated genotype for the screening, prediction, diagnosis, prognosis, treatment and treatment response of psychiatric, neuropsychiatric, and neurological disorders, such as schizophrenia, schizoaffective disorder and bipolar disorder, and for defining treatments of such disorders. The presence of a variant in the GCH1 gene, alone or in conjunction with a measurement of low or altered biopterin, or altered BH4 system measures, is used to screen or diagnose subjects at risk for developing a psychiatric, neuropsychiatric, or neurological disorder. The genetic assay, with or without a biopterin or BH4 system assay, may also be used to determine treatment regimens. For subjects with an impaired BH4 system, treatments to increase or normalize biopterin, BH4, or the BH4 system can also be used, such as BH4 supplementation, lithium treatment, phenylalanine treatment, or other treatments and therapies. | 05-10-2012 |
| 20120177750 | METHODS FOR TREATING PAIN USING TOPICAL PRODUCT FORMULATIONS CONTAINING STRONTIUM - Topical formulations containing aqueous-soluble divalent strontium cation in a suitable topical keratinized skin formulation vehicle, and methods of using these formulations to inhibit skin irritation in keratinized skin, are disclosed. | 07-12-2012 |
| 20120219641 | 5-HT3 RECEPTOR MODULATORS, METHODS OF MAKING, AND USE THEREOF | 08-30-2012 |
| 20130017274 | LOW DOSE LITHIUM IN THE TREATMENT OR PROPHYLAXIS OF PARKINSON'S DISEASE - In various embodiments methods of delaying the onset of and/or mitigating the severity of one or more symptoms of Parkinson's disease in a mammal are provided. In certain embodiments the methods involve administering to a mammal diagnosed as having or as at risk for Parkinson's disease a chronic low dose of lithium (e.g., a subtherapeutic dose). In certain embodiments the low dose lithium is administered in conjunction with another agent (e.g., L-DOPA). | 01-17-2013 |
| 20130039998 | COMPOSITIONS OF MODULATORS OF THE WNT/BETA-CATENIN PATHWAY AND BENZAMIDE AND/OR HYDROXAMIC ACID DERIVATIVES TO TREAT BIPOLAR DISORDER - The present invention is directed to a composition comprising a modulator of the Wnt/β-catenin pathway, such as a GSK-3 inhibitor, or a pharmaceutically acceptable salt thereof either with a benzamide derivative or a pharmaceutically acceptable salt thereof or with a hydroxamic acid or a pharmaceutically acceptable salt thereof. The present invention is also directed to a method of treating bipolar disorder in a subject by administering either a benzamide derivative or a hydroxamic acid to the subject under conditions effective to treat a bipolar disorder. A modulator of the Wnt/β-catenin pathway, such as a GSK-3 inhibitor, or a pharmaceutically acceptable salt thereof may also be administered to a subject. | 02-14-2013 |
| 20130295201 | Methods for Inhibiting Sensory Nerves by Topically Administering Strontium-Containing Compositions to Keratinized Skin - Topical formulations containing aqueous-soluble divalent strontium cation in a suitable topical keratinized skin formulation vehicle, and methods of using these formulations to inhibit skin irritation in keratinized skin, are disclosed. | 11-07-2013 |
| 20140037757 | DRUG THERAPY TO INHIBIT CHEMOTHERAPY-INDUCED ADVERSE EFFECTS AND RELATED PHARMACEUTICAL COMPOSITIONS, DIAGNOSTICS, SCREENING TECHNIQUES AND KITS - The invention provides a method of treatment comprising reducing therapy-induced adverse effects (TIAE), including chemotherapy-induced adverse effects (CIAE), such as chemotherapy-induced peripheral neuropathy (CIPN) and/or chemotherapy-induced cardiovascular adverse effects (CICAE) in a subject being treated with a CIAE-inducing anti-cancer active ingredient by co-administering to the subject a pharmaceutically effective amount of a NCS-1-protective composition. Related pharmaceutical compositions, diagnostics and screening techniques are also provided. | 02-06-2014 |
| 20140056998 | SYSTEM AND METHOD FOR DIAGNOSIS AND TREATMENT OF NEUROPSYCHIATRIC DISORDERS - An assay for a GCH1 allele and associated genotype for the screening, prediction, diagnosis, prognosis, treatment and treatment response of psychiatric, neuropsychiatric, and neurological disorders, such as schizophrenia, schizoaffective disorder and bipolar disorder, and for defining treatments of such disorders. The presence of a variant in the GCH1 gene, alone or in conjunction with a measurement of low or altered biopterin, or altered BH4 system measures, is used to screen or diagnose subjects at risk for developing a psychiatric, neuropsychiatric, or neurological disorder. The genetic assay, with or without a biopterin or BH4 system assay, may also be used to determine treatment regimens. For subjects with an impaired BH4 system, treatments to increase or normalize biopterin, BH4, or the BH4 system can also be used, such as BH4 supplementation, lithium treatment, phenylalanine treatment, or other treatments and therapies. | 02-27-2014 |
| 20140120182 | METHOD FOR THE TREATMENT OF CANCER - The invention is based on the surprising finding that treatment with a chemotherapeutic agent such as 5-fluorouracil (5-FU) and an autophagy inducer effectively inhibit the continued growth of, and prevent the recovery following drug withdrawal, of cancer cells. In vivo, drug resistance from a failure to adequately engage in apoptotic programmed cell death leads to a recurrence of cancer and tumours can remain dormant for periods of time before re-emerging as drug resistant metastases. It has been hypothesised that autophagy (Type II cell death) may help cancer cells survive in response to growth limiting conditions, such as nutrient depletion, hypoxia, absence of growth factor, or presence of cytotoxic drug. LiCl is a known autophagy inducer and accelerates cell survival to autophagic programmed cell death. | 05-01-2014 |
| 20140193523 | PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT AND PREVENTION OF TRAUMA-INDUCED NEUROPATHOLOGY AND NEURODEGENERATION - Novel multi-component formulations, procedures and methods for use in treating neuropathology and neurodegeneration incident to trauma are provided. Multi-component formulations of the invention comprise biologically active forms of any two, any three, or all four of at least one neurosteroid or neuroactive steroid, such as progesterone or synthetic progestin, at least one anti-epileptic or anticonvulsant, such as gabapentin, pregabalin or valproic acid, at least one NK-1 receptor antagonist, such as aprepitant, casopitant or vestipitant, at least one lithium-containing or lithium-related drug. The provided formulations are configured or adapted to prevent or reduce the incidence and severity of neurological damage caused by trauma, or the risk of such damage. Formulations, procedures and methods of the invention advantageously effect both neuroprotective actions to prevent or reduce secondary injuries, and neurotrophic actions to repair and restore cells and tissues affected by the trauma, and are especially useful in treating injury or trauma to nerve cells, to neural support cells and to neural support tissues. | 07-10-2014 |
| 20140242193 | LITHIUM COMPOSITIONS - 2:1 cocrystals of amino acids and Li+ salts crystallize from hot water to afford water stable cationic networks based upon tetrahedral lithium cations: bilayered square grids, a lithium zeolitic metal-organic material (LiZMOM) and several lithium diamondoid metal-organic materials (LiDMOMs). The compositions may be used as a pharmaceutical for the treatment of suicidality and other disorders that require lithium to penetrate the blood brain barrier and exert therapeutic effects in the CNS. Advantageously, the novel cocrystal forms described herein may be used to lower the oral dose required to achieve therapeutic concentrations of lithium in the brain, thus reducing the peripheral toxicity and potentially broadening the therapeutic index in comparison to conventional lithium forms. | 08-28-2014 |
| 20140322358 | Compositions and methods for amelioration of chronic renal failure and related symptoms in domestic animals - The present invention is generally directed to compositions and methods for amelioration chronic renal failure and related symptoms in domestic animals. In one case, the present invention is directed to a composition for the treatment of chronic renal failure in a domestic animal or symptoms related to chronic renal failure. The composition comprises a Fruit- and Vegetable-Based Additive. In another case, the present invention is directed to a composition for the treatment of chronic renal failure in a domestic animal or symptoms related to chronic renal failure. The composition comprises a Cesium and/or Rubidium salt. In another case, the present invention is directed to a composition for the treatment of chronic renal failure in a domestic animal or symptoms related to chronic renal failure. The composition comprises a Dehydrated Domestic Animal Food and a Phosphate Binder. | 10-30-2014 |
| 20150044302 | COMPOSITIONS AND METHODS FOR PROMOTING APPETITE SUPPRESSION USING ALKALI METALS - The present invention relates to a method of suppressing appetite or promoting a stimulant effect in an individual in need thereof, comprising administering to the individual per 24 hour period an effective amount of one or more alkali metals selected from the group consisting of one or more sources of cesium, one or more sources of rubidium, one or more sources of lithium, and combinations thereof. The present invention further relates to weight loss or stimulant compositions comprising one or more alkali metals. | 02-12-2015 |
| 20150099012 | METHODS FOR ACTIVATING RETROVIRUS IN LATENT INFECTED CELLS, AND COMPOUNDS FOR USE THEREIN - The present invention relates to a method for increasing retrovirus transcription in an infected eukaryotic cell, comprising increasing Wnt pathway signaling in said cell such that transcription of said retrovirus is increased. Also, the present invention relates to a method of treating a subject infected with a retrovirus, said method comprising administering to said subject an activator of the Wnt pathway in an amount that increased Wnt pathway signaling in resting memory CD4+ T cells of said subject such that the retroviral long terminal repeat (LTR) in said cells is activated or de-repressed. | 04-09-2015 |
| 20150342985 | COMPOSITIONS COMPRISING LITHIUM - This invention relates to compositions comprising lithium and methods of their use. | 12-03-2015 |
| 20160038536 | PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT AND PREVENTION OF TRAUMA-INDUCED NEUROPATHOLOGY AND NEURODEGENERATION - Novel multi-component formulations, procedures and methods for use in treating neuropathology and neurodegeneration incident to trauma are provided. Multi-component formulations of the invention comprise biologically active forms of any two, any three, or all four of at least one neurosteroid or neuroactive steroid, such as progesterone or synthetic progestin, at least one anti-epileptic or anticonvulsant, such as gabapentin, pregabalin or valproic acid, at least one NK-1 receptor antagonist, such as aprepitant, casopitant or vestipitant, at least one lithium-containing or lithium-related drug. The provided formulations are configured or adapted to prevent or reduce the incidence and severity of neurological damage caused by trauma, or the risk of such damage. Formulations, procedures and methods of the invention advantageously effect both neuroprotective actions to prevent or reduce secondary injuries, and neurotrophic actions to repair and restore cells and tissues affected by the trauma, and are especially useful in treating injury or trauma to nerve cells, to neural support cells and to neural support tissues. | 02-11-2016 |
| 20160375052 | COMPOSITIONS AND METHODS FOR TREATMENT OF SHORT TELOMERE DISORDERS - The invention generally relates to methods of treating short telomere disorders using known compounds and pharmaceutical compositions comprising same. More specifically, the disclosed methods comprise, in one aspect, the step of administering to the subject an effective amount of at least one lithium compound or a pharmaceutically acceptable salt thereof, thereby treating the subject for the short telomere disorder. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention. | 12-29-2016 |
